teicoplanin
Small moleculeexperimental
Teicoplanin is a glycopeptide antibiotic with a spectrum of activity similar to vancomycin. Its mechanism of action is to inhibit bacterial cell wall peptidoglycan synthesis. It is used in the prophylaxis and treatment of serious infections caused by Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus and Enterococcus faecalis. — Wikipedia
Clinical trial activity
19 trials · 26 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
4
Phase 3
2
Phase 4
8
Earliest trial started Feb 1, 1999 (NCT00024453)
Timeline
Indications
Approved for
Studied for
- Amputation, Surgical · Phase 4
- Arthroplasty · Phase 4
- Bacteremia · Phase 4
- Catheter-Related Infections · Phase 4
- Clostridium Infections · Phase 4
- Cystic Fibrosis · Phase 1
- Febrile Neutropenia · Phase 4
- Infections · Phase 4
- Liver Cirrhosis, Biliary · Phase 4
- Lumbar Vertebrae · Phase 3
- Neurosurgery · Phase 1
- Osteomyelitis · Phase 2
- Patient Compliance · Phase 4
- Pharmacology · Phase 4
- Scoliosis · Phase 3
- Skin Diseases, Infectious · Phase 3
- Soft Tissue Infections · Phase 3
- Spinal Stenosis · Phase 3
- Spondylolisthesis · Phase 3
- Staphylococcal Infections · Phase 4
- Wound Infection · Phase 4
Mechanism of action
- PeptidoglycanDISRUPTING AGENT
Peptidoglycan disrupting agent
Chemistry & pharmacology
Loading structure…
SMILES
N[C@H]1C(=O)N[C@@H]2Cc3ccc(c(Cl)c3)Oc3cc4cc(c3O)Oc3ccc(cc3Cl)[C@@H](O)[C@@H]3NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@@H](NC2=O)c2cc(O)cc(c2)Oc2cc1ccc2O)c1ccc(O)c(c1)-c1c(O)cc(O)cc1[C@@H](C(=O)O)NC3=O- Mol. weight
- 1198.94 g/mol
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaTeicoplanin ↗
- ChEMBLCHEMBL4297166 ↗
- ChEMBLCHEMBL2367892 ↗
- ChEMBLCHEMBL2348244 ↗
Also known as
- aglucoteicoplanin
- antibiotic 8327a
- antibiotic a 41030b
- antibiotic mdl 507
- mdl-507
- mdl-507
- targocid
- targocid
- targocid
- targosid
- teic
- teic
- teichomycin
- teichomycin
- teichomycin
- teichomycin a2 factor 2
- teichomycin a2 factor 2
- teicoplanin
- teicoplanin
- teicoplanin
- teicoplanin
- teicoplanin
- teicoplanin
- teicoplanin
- teicoplanin
- teicoplanin aglycon
- teicoplanin aglycon
- teicoplanin aglycon
- teicoplanin aglycone
- teicoplanin aglycone
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06818565 | N/A | Feb 10, 2025 | Institute of Liver and Biliary Sciences, India |
| NCT05914467 | Phase 4 | Aug 1, 2023 | Radboud University, ZonMw: The Netherlands Organisation for Health Research and Development |
| NCT04370145 | Phase 4 | Jun 30, 2020 | Huazhong University of Science and Technology, Jiao Tong University |
| NCT04341831 | Phase 3 | Apr 15, 2020 | Bezmialem University |
| NCT04176328 | Phase 1 | Sep 19, 2019 | Aptuit Inc., NeuPharma, Inc., Pari Pharma GmbH, Sintesi Research Srl, University of Verona |
| NCT04003818 | Phase 4 | Jun 28, 2019 | Sanofi |
| NCT06426836 | N/A | Aug 19, 2016 | Ghent University |
| NCT02288923 | N/A | Mar 1, 2015 | University of Exeter |
| NCT02652169 | N/A | Jun 1, 2014 | University of Vienna |
| NCT02018094 | Phase 4 | Oct 1, 2013 | University of Hull |
| NCT01815541 | Phase 2 | Mar 1, 2013 | University of Picardie Jules Verne |
| NCT01592032 | Phase 4 | May 1, 2012 | Clinica Universidad de Navarra |
| NCT00925093 | Phase 1 | Sep 1, 2011 | Aarhus University |
| NCT00428844 | Phase 2 | Jan 1, 2007 | Cubist |
| NCT00368498 | Phase 4 | Jun 1, 2006 | National Taiwan University |
| NCT00430937 | Phase 3 | Apr 1, 2006 | Novartis |
| NCT00454272 | Phase 4 | Jan 1, 2005 | Sanofi |
| NCT00719056 | Phase 4 | Aug 1, 2004 | KAT General Hospital, University of Athens |
| NCT00024453 | N/A | Feb 1, 1999 | Children's Cancer and Leukaemia Group, Royal Liverpool & Broadgreen University Hospitals NHS Truts |
Showing 19 of 19 trials
Page 1 / 1
Organizations
Research & Development (26)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sanofi | For profit | 2 | 2 | 1 | 2005 |
| Aarhus University | Academic/Hospital | 1 | 1 | 1 | 2011 |
| Aptuit Inc. | For profit | 1 | 0 | 1 | 2019 |
| Bezmialem University | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Children's Cancer and Leukaemia Group | Academic/Hospital | 1 | 1 | 1 | 1999 |
| Clinica Universidad de Navarra | Academic/Hospital | 1 | 1 | 1 | 2012 |
| Cubist | For profit | 1 | 1 | 1 | 2007 |
| Ghent University | Academic/Hospital | 1 | 1 | 1 | 2016 |
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Institute of Liver and Biliary Sciences, India | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Jiao Tong University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| KAT General Hospital | Academic/Hospital | 1 | 0 | 1 | 2004 |
| National Taiwan University | Academic/Hospital | 1 | 1 | 1 | 2006 |
| NeuPharma, Inc. | For profit | 1 | 1 | 1 | 2019 |
| Novartis | For profit | 1 | 1 | 1 | 2006 |
| Pari Pharma GmbH | For profit | 1 | 0 | 1 | 2019 |
| Radboud University | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Royal Liverpool & Broadgreen University Hospitals NHS Truts | Academic/Hospital | 1 | 0 | 1 | 1999 |
| Sintesi Research Srl | For profit | 1 | 0 | 1 | 2019 |
| University of Athens | Academic/Hospital | 1 | 1 | 1 | 2004 |
26 organizations
Page 1 / 2